The MHRA published on 2 November 2025, a Policy Paper outlining the Agency’s intentions to improve regulatory pathways for rare disease therapies to be tested, manufactured and approved in the UK.
The NHS announced on 17 October 2025 that it would roll out a new long-acting injection to prevent HIV, as part of its ambition to become the first country in the world to end HIV transmissions by 2030.
The Government has appointed industry expert Steve Bates OBE as the new Executive Chair for the Office for Life Sciences. In his new role announced on 22 July 2025, Bates will act as an ambassador both domestically and internationally for the UK life sciences sector.
The UK Government unveiled its new Life Sciences Sector Plan on 16 July 2025, designed as a central pillar of its broader Industrial Strategy.
The MHRA has been approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
As we enter the second half of 2025, Brevia Health has collected and analysed data on parliamentary discussions surrounding the leading diseases in the UK.
